Korean Market Moves: Dongguk Pharma Prostate Drug Claims 76% Market Share, FTC Tightens Cartel Leniency

The Quick Take

• Dongguk Pharmaceutical Urescoplex prostate combination drug captured 76.3% market share in its Korean segment in June and signed licensing deals covering 13 Latin American countries
• Korea Fair Trade Commission will reduce cartel leniency from full exemption to 75% reduction for first-time reporters who come forward after investigation starts
• Repeat cartelists who re-offend within 10 years extended from 5 years will face halved leniency benefits under the proposed Fair Trade Act amendment

Synthesized from 2 sources.

Two significant regulatory and commercial developments emerged from South Korea on September 23. Dongguk Pharmaceutical Urescoplex—a world-first combination of dutasteride and tadalafil for benign prostatic hyperplasia—achieved 76.3% market share in its combination drug segment as of June, validated by UBIST market research, and secured a licensing and supply agreement covering 13 Latin American countries with Spain Faus Pharma. The drug clinical evidence has also been published in the BJU International journal, strengthening its global commercial positioning and regulatory pathway in new geographies. This represents a meaningful specialty pharma commercial success by a Korean mid-cap company now expanding internationally.

The FTC proposed amendment to Korean cartel leniency rules has direct implications for conglomerates and corporations that historically relied on leniency programs to navigate cartel investigations. Reducing post-investigation disclosure benefits from 100% to 75% exemption increases the financial penalty for firms that delay reporting until regulatory action begins. This is expected to incentivize earlier voluntary disclosure, disrupting the equilibrium strategy of cartelists who historically waited to assess investigation risk before coming forward. For compliance departments at Korean chaebols and mid-sized firms, the amendment raises the effective cost of cartel participation and tightens the leniency program risk calculus significantly.

Forward signals include the FTC legislative enactment timeline—currently in public comment until early October—which determines when new leniency thresholds take effect. For Dongguk Pharma, the Latin American licensing deal commercial ramp will be observable through quarterly revenue disclosures and any additional territory expansion announcements. The macro variable governing the FTC reform market impact is frequency of cartel detection rates in Korea: if the amendment successfully increases pre-investigation disclosure rates, the resulting deterrence effect should appear in the number of cartel cases investigated over the subsequent two to three years of enforcement data.